Aspirin Enhances Chemosensitivity of Colorectal Cancer Cells by Downregulating FOXP3 to Inhibit ABCB1 Expression

Why It Matters

By repurposing a widely available, inexpensive drug, the study offers a potential strategy to boost chemotherapy efficacy and reduce toxic dosing in colorectal cancer patients, addressing a critical barrier to treatment success.

Key Takeaways

• Aspirin reduces colorectal cancer mortality in NHANES cohort
• Combining aspirin with doxorubicin shows synergistic tumor suppression
• FOXP3 identified as key regulator of ABCB1-mediated drug efflux
• Aspirin downregulates FOXP3, decreasing ABCB1 expression
• Targeting FOXP3‑ABCB1 axis may improve chemoresistance outcomes

Pulse Analysis

The persistence of chemoresistance remains a major obstacle in treating colorectal cancer, with ATP‑binding cassette transporters such as ABCB1 actively pumping cytotoxic agents out of tumor cells. Recent interest in drug repurposing has highlighted non‑steroidal anti‑inflammatory drugs as modulators of cancer pathways. Aspirin, long valued for cardiovascular protection, has emerged as a candidate that can interfere with molecular mechanisms governing drug efflux, offering a low‑cost adjunct to existing regimens. Understanding how aspirin interacts with the ABC transporter network is essential for translating preclinical findings into therapeutic gains.

The study leveraged a multi‑layered approach, beginning with epidemiological analysis of the NHANES database, which revealed a statistically significant reduction in colorectal‑specific mortality among regular aspirin users. In parallel, in vitro and in vivo experiments demonstrated that aspirin enhances doxorubicin accumulation by suppressing the FOXP3 transcription factor, which directly controls ABCB1 expression. Molecular docking and dynamics simulations confirmed a stable interaction between aspirin and FOXP3, while uptake assays showed increased intracellular doxorubicin levels when the two agents were combined. These data pinpoint the FOXP3‑ABCB1 axis as the mechanistic bridge linking aspirin to chemosensitivity.

Clinically, the findings suggest that integrating low‑dose aspirin into standard chemotherapy protocols could lower the effective dose of doxorubicin required, potentially reducing cardiotoxicity while preserving antitumor efficacy. Ongoing trials should stratify patients by FOXP3 expression to identify those most likely to benefit from this combination. Moreover, the research underscores the broader value of repurposing established drugs to overcome multidrug resistance, a strategy that could accelerate the development pipeline across oncology. If validated, targeting FOXP3 may become a cornerstone of precision medicine for colorectal cancer.